Management of non-alcoholic fatty liver disease in 2015

World Journal of Hepatology

Volumn 7, Issue 30, 2015, Pages 2962-2967

  Malhotra, Neel ^a,b   Beaton, Melanie D ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Liver fibrosis; Lobular inflammation; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis

Indexed keywords

EID: 84952792542     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i30.2962     Document Type: Article

References (34)

1. Federico A, Zulli C, de Sio I, Del Prete A, Dallio M, Masarone M, Loguercio C. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20: 16841-16857 [PMID: 25492998 DOI: 10.3748/wjg.v20. i45.16841]
2. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012; 55: 2005-2023 [PMID: 22488764 DOI: 10.1002/hep.25762]
3. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010; 51: 121-129 [PMID: 19827166 DOI: 10.1002/ hep.23276]
4. Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol. 2011; 106: 460-468; quiz 469 [PMID: 21206486 DOI: 10.1038/ajg.2010.488]
5. Sullivan S. Implications of diet on nonalcoholic fatty liver disease. Curr Opin Gastroenterol. 2010; 26: 160-164 [PMID: 20010099 DOI: 10.1097/MOG.0b013e3283358a58]
6. Funaki M. Saturated fatty acids and insulin resistance. J Med Invest. 2009; 56: 88-92 [PMID: 19763019 DOI: 10.2152/jmi.56.88]
7. Kechagias S, Ernersson A, Dahlqvist O, Lundberg P, Lindström T, Nystrom FH. Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut. 2008; 57: 649-654 [PMID: 18276725 DOI: 10.1136/gut.2007.131797]
8. Clarke SD. Nonalcoholic steatosis and steatohepatitis. I. Molecular mechanism for polyunsaturated fatty acid regulation of gene transcription. Am J Physiol Gastrointest Liver Physiol. 2001; 281: G865-G869 [PMID: 11557505]
9. Vos MB, Lavine JE. Detary fructose in nonalcoholic fatty liver disease. Hepatology. 2013; 57: 2525-2531 [PMID: 23390127 DOI: 10.1002/hep.26299]
10. Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, Diehl AM. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology. 2010; 51: 1961-1971 [PMID: 20301112 DOI: 10.1002/hep.23535]
11. Bravi F, Bosetti C, Tavani A, Gallus S, La Vecchia C. Coffee reduces risk for hepatocellular carcinoma: an updated metaanalysis. Clin Gastroenterol Hepatol. 2013; 11: 1413-1421.e1 [PMID: 23660416 DOI: 10.1016/j.cgh.2013.04.039]
12. Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology. 2012; 55: 429-436 [PMID: 21987293 DOI: 10.1002/hep.24731]
13. Torres DM, Harrison SA. Is it time to write a prescription for coffee? Coffee and liver disease. Gastroenterology. 2013; 144: 670-672 [PMID: 23453671 DOI: 10.1053/j.gastro.2013.02.015]
14. Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology. 2014; 147: 377-384.e1 [PMID: 24818764 DOI: 10.1053/j.gastro.2014.04.046]
15. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010; 362: 1675-1685 [PMID: 20427778 DOI: 10.1056/NEJMoa0907929]
16. Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep. 2013; 1: 57-64 [PMID: 24648894 DOI: 10.3892/br.2018.18]
17. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 2005; 100: 1082-1090 [PMID: 15842582 DOI: 10.1111/j. 1572-0241.2005.415 83.x]
18. Zhang X, Harmsen WS, Mettler TA, Kim WR, Roberts RO, Therneau TM, Roberts LR, Chaiteerakij R. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology. 2014; 60: 2008-2016 [PMID: 24798175 DOI: 10.1002/hep.27199]
19. Paschos P, Tziomalos K. Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. World J Hepatol. 2012; 4: 327-331 [PMID: 23355909 DOI: 10.4254/wjh. v4.i12.327]
20. Al-Mallah M, Khawaja O, Sinno M, Alzohaili O, Samra AB. Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis. Cardiol J. 2010; 17: 448-456 [PMID: 20865674]
21. Warner FJ, Lubel JS,McCaughan GW, Angus PW. Liver fibrosis: a balance of ACEs. Clin Sci (Lond). 2007; 113: 109-118 [PMID: 17600527 DOI: 10.1042/CS20070026]
22. Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol. 2009; 15: 942-954 [PMID: 19248193 DOI: 10.3748/ wjg.15.942]
23. Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014; 12: 394-402.e1 [PMID: 24076414 DOI: 10.1016/j.cgh.2013.09.023]
24. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011; 141: 1249-1253 [PMID: 21726509 DOI: 10.1053/ j.gastro.2011.06.061]
25. Caiazzo R, Lassailly G, Leteurtre E, Baud G, Verkindt H, Raverdy V, Buob D, Pigeyre M, Mathurin P, Pattou F. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg. 2014; 260: 893-898; discussion 898-899 [PMID: 25379859 DOI: 10.1097/SLA.0000000000000945]
26. Kinross JM, von Roon AC, Holmes E, Darzi A, Nicholson JK. The human gut microbiome: implications for future health care. Curr Gastroenterol Rep. 2008; 10: 396-403 [PMID: 18627653 DOI: 10.1186/gm228]
27. Zu L, Baker RD, Baker SS. Gut microbiome and nonalcoholic fatty liver diseases. Pediatr Res. 2015; 77: 245-251 [PMID: 25310763 DOI: 10.1038/pr.2014.157]
28. Schwiertz A, Taras D, Schäfer K, Beijer S, Bos NA, Donus C, Hardt PD. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring). 2010; 18: 190-195 [PMID: 19498350 DOI: 10.1038/oby.2009.167]
29. Ley RE, Turnbaugah PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006; 444: 1022-1023 [PMID: 17183309]
30. Zeng T, Zhang CL, Zho XL, Xie KQ. Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized double-blind, placebo-controlled studies. Eur J Gastroenterol Hepatol. 2014; 26: 646-653 [PMID: 24743504 DOI: 10.1097/MEG.0000000000000068]
31. Du J, Ma YY, Yu CH, Li YM. Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2014; 20: 569-577 [PMID: 24574727 DOI: 10.3748/wjg.v20. i2.569]
32. Porez G, Prawitt J, Gross B, Staels B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res. 2012; 53: 1723-1737 [PMID: 22550135 DOI: 10.1194/ jlr.R024794]
33. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebocontrolled trial. Lancet. 2015; 385: 956-965 [PMID: 25468160 DOI: 10.1016/S0140-6736(14)61933-4]
34. Xiao J, Fai So K, Liong EC, Tipoe GL. Recent advances in the herbal treatment of non-alcoholic Fatty liver disease. J Tradit Complement Med. 2013; 3: 88-94 [PMID: 24716162 DOI: 10.4103/ 2225-4110.110411]